作者: Bernard Bourrie , Pierre Casellas
DOI:
关键词: Leukemia 、 Pharmacology 、 Myeloid leukaemia 、 Medicine
摘要: The disclosure relates to methods of treating leukaemia, in particular myeloid comprising administering the compound N-[2-(2,1,3-benzothiadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N′-(1,1-dimethylethyl)-urea or a hydrate, pharmaceutically acceptable salt solvate thereof.